InnovationWell Discusses Innovation in Life Science & Healthcare Research & Product Development

Share Article

The InnovationWell Community of Practice InterAction Meeting "Innovation in Life Science & Healthcare Research & Product Development" will take place 16-19 October 2006, Bryn Mawr College, Philadelphia, USA.

The InnovationWell Community of Practice InterAction Meeting "Innovation in Life Science & Healthcare Research & Product Development" will take place 16-19 October 2006, Bryn Mawr College, Philadelphia, USA. The program will concentrate on themes of relevance to FDA’s Critical Path initiative integrated into the ongoing InnovationWell program themes of innovation and knowledge management in life science and healthcare product development and safety.

Topics in Knowledge Management in Clinical and Translational Research, Decision Support for R&D, Metabolomics, Predictive Toxicology, Medicinal Chemistry and Biomarkers & Systems Biology approaches will be covered in four days of InterAction Meeting program sessions. In addition to morning presentations and panel discussions, workshops will run each afternoon expanding on topics and methods, with bbq, social activity and poster sessions running on campus during the evenings.

A Metabolomics in Discovery & Development Program includes presentations and workshops from Rick Beger (NCTR, FDA), Alvin Berger (Metabolon), Don Robertson (Pfizer), Gregory Banik (Bio-RAD), Teresa Garrett (Duke University), Susan Connor (Glaxo SmithKline), Greg Maguire (SIDMAP), Bruce Kristal (Cornell University), Stanley Young (NISS), Andrew Lane (JG Brown Cancer Center, U. Louisville), Oliver Fiehn (UC Davis Genome Center), and Eric Nemec (Leco Corporation). "The meeting program will bring together top experts in industry, government and academia to discuss recent progress and current challenges in the field of metabolomics aimed towards applications for personalised medicine, new diagnostics and enhancing drug safety. Case studies describing recent progress in approaches as well as highlighting certain pitfalls will be presented." said program chair George Harrigan of Monsanto.

The FDA has identified the development of new biomarkers as one of the key opportunities to increase efficiency, predictability, and productivity in drug development. However "Despite the technological advances, especially in genomics, developing and 'qualifying' candidate biomarkers to generate a true clinical utility is still not a straightforward process." said Zentam Tsuchihashi of BristolMyersSquibb. A session on the application of Biomarkers in Drug Development will explore new advances and challenges in this area and will include a keynote from Keith Elliston, CEO (Genstruct), with Zentam Tsuchihashi discussing Biomarker Roles in Tumor Immunotherapy, Darius Dziuda (CCSU) will cover the topic of Multivariate BioMarkers, Michael Jones (Novartis) will discuss Proteomics applications whereas Bernd Bonnekoh (Otto-von-Guericke University) and Ansgar J. Pommer (SkinSysTec) will provide perspectives for Multi Epitope Ligand Kartography (MELK) and skin disease applications.

Michael Liebman, executive director of the Windber Research Institute, will chair a program examining the application of Knowledge Management techniques to increase R&D productivity along Critical Paths in clinical and translational research and will be joined by Delia Y. Wolf (Harvard Medical School), Peter Gates (Johnson & Johnson PR&D), Jonathan Sheldon (InforSense), Duane Shugars (Concentia Digital), Jian Wang (Biofortis), and Jeff Spitzner (Rescentris). Liebman pipped "The industry is very focused on the collection, integration and curation of data, but has not yet begun to take on the important role of extracting knowledge from this information."

The program also includes a Decision Support for Research & Development program which will examine the application of knowledge and risk management, systems biology, analytics, and new technologies in improving productivity and decision making in R&D, clinical research and development, and drug discovery and development sessions on Structure-based Drug Design, Screening, and Medicinal Chemistry.

Douglas Connect (

Douglas Connect specializes in solutions of relevance to pharmaceutical and life science research and development, drug discovery, life science product development and healthcare product safety, providing services, consulting and training in knowledge management, collaboration support, informatics and electronic support systems for research and development. Douglas Connect also runs the eCheminfo network ( dedicated to innovation topics and practices in drug discovery chemistry and informatics, and InnovationWell, a community of practice for innovation and knowledge management in the life science product life cycle. Douglas Connect is based in Zeiningen, Switzerland.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Nicki Douglas
Visit website